Haleon Cancels 8.7 Million Shares Under Ongoing Buyback Programme

The latest update is out from Haleon PLC ( (GB:HLN) ).

Haleon plc has repurchased 8,740,351 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026, with purchases executed across the London Stock Exchange and multiple alternative UK trading venues between 13 and 17 April. Following these transactions, Haleon’s registered share capital stands at 8,911,083,689 ordinary shares, of which 12,320,645 are held in treasury, leaving 8,898,763,044 shares with voting rights, a change that may affect shareholder reporting thresholds and underscores the company’s continuing capital-management efforts.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc, listed in London and New York, is a global consumer health company focused on improving everyday health through over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain and respiratory relief, digestive health and therapeutic skin care, led by brands such as Sensodyne, Panadol, Voltaren, Advil and Centrum, used by over a billion consumers worldwide.

Average Trading Volume: 20,598,082

Technical Sentiment Signal: Sell

Current Market Cap: £31.45B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.